Gapping down
In reaction to disappointing earnings/guidance: VIPS -14%,
ACXM -10.3%,
FLY -9.5%,
TGT -7.2%,
ICL -6.1%,
GAIN -1.2%,
ADI -0.7%
M&A news: SHLX -6% (to acquire additional equity interests in Zydeco Pipeline Co, Bengal Pipeline Co, & Colonial Pipeline Co from Royal Dutch Shell (RDS.A) for $700 mln, expects immediate earnings accretion; commences 9.5 mln underwritten public offering of common units),
VRX -1% (mulling a sale of their skin & cancer drugs)
Select metals/mining stocks trading lower: GFI -2.6%,
BBL -2.5%,
RIO -2.2%,
SLW -1.9%,
FCX -1.7%,
VALE -1.6%,
IAG -1.5%,
BHP -1.5%,
SLV -1.3%,
ABX -1.3%,
AUY -1.2%,
AUY -1.2%,
GOLD -1.1%
Other news: MACK -4.8% (Merrimack Pharma presents expanded analysis of its Phase 2 study of seribantumab in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer ),
BBY -4.3% (in sympathy with TGT earnings),
ATI -3.2% (to offer a series of convertible senior notes),
COST -2.2% (in sympathy with TGT earnings),
DG -1.9% (in sympathy with TGT earnings),
JCP -1% (in sympathy with TGT earnings),
KSS -0.9% (in sympathy with TGT earnings)
Analyst comments: NRZ -0.9% (downgraded to Neutral at Compass Point)